GSK plc (LON:GSK – Get Free Report)’s stock price crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 1,549.75 ($19.14) and traded as high as GBX 1,661.50 ($20.52). GSK shares last traded at GBX 1,636 ($20.21), with a volume of 3,466,006 shares.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on GSK shares. Berenberg Bank raised their price target on shares of GSK from GBX 1,650 ($20.38) to GBX 1,820 ($22.48) and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a GBX 1,950 ($24.09) price target on shares of GSK in a research report on Wednesday, April 17th. Shore Capital reaffirmed a “buy” rating on shares of GSK in a research report on Thursday, March 7th. Finally, Barclays reissued an “equal weight” rating and issued a GBX 1,725 ($21.31) target price on shares of GSK in a report on Monday, April 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of GBX 1,630.63 ($20.14).
View Our Latest Stock Analysis on GSK
GSK Trading Up 0.1 %
GSK Increases Dividend
The firm also recently announced a dividend, which was paid on Thursday, April 11th. Investors of record on Thursday, February 22nd were given a dividend of GBX 16 ($0.20) per share. The ex-dividend date was Thursday, February 22nd. This is an increase from GSK’s previous dividend of $14.00. This represents a yield of 1.04%. GSK’s dividend payout ratio (DPR) is currently 5,333.33%.
Insider Buying and Selling
In other GSK news, insider Urs Rohner bought 434 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The shares were acquired at an average cost of GBX 1,662 ($20.53) per share, for a total transaction of £7,213.08 ($8,909.44). In other news, insider Urs Rohner purchased 434 shares of the company’s stock in a transaction dated Wednesday, March 20th. The shares were purchased at an average price of GBX 1,662 ($20.53) per share, for a total transaction of £7,213.08 ($8,909.44). Also, insider Julie Brown purchased 19,360 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was purchased at an average price of GBX 1,583 ($19.55) per share, for a total transaction of £306,468.80 ($378,543.48). Insiders have acquired a total of 19,802 shares of company stock worth $31,381,484 in the last ninety days. Company insiders own 1.71% of the company’s stock.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Featured Articles
- Five stocks we like better than GSK
- Bank Stocks – Best Bank Stocks to Invest In
- High-Yield Texas Instruments Could Hit New Highs Soon
- What Is WallStreetBets and What Stocks Are They Targeting?
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- What is a Death Cross in Stocks?
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.